SIPULEUCEL-T PUBLICATIONS



LAPULEUCEL-T PUBLICATIONS

  • Peethambaram PP, Melisko ME, Rinn KJ, et al. A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu. Clin Cancer Res 2009; 15:5895-901.
  • Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer. J Clin Oncol. 2007;25(24):3680-3687. PMID: 17704416
  • Diegel, ML, Chen, F, Laus, R, Graddis, TJ, & Vidovic, D "MHC class I-restricted presentation of protein antigens without prior intracellular processing," Scand J. Immunol., 58:1-8, 2003.
  • Vidovic, D, Graddis, TJ, Stepan, LP, Zaller, DM & Laus, R "Specific stimulation of MHC transgenic mouse T cell hybridomas with xenogeneic APC," Human Immunol. 64:238-244, 2003
  • Vidovic, D, Graddis, TJ, Chen, F, Slagle, PH, Diegel, ML, Stepan, L.P. & Laus, R. "Anti-tumor vaccination with HER-2 derived recombinant antigens," Int. J. Cancer 102:660-664, 2002
  • Valone F, Small E, MacKenzie M, Burch P, Lacy M, Peshwa MV, Laus R, "Dendritic Cell-Based Treatment of Cancer: Closing in on a Cellular Therapy," The Cancer Journal: 7, S53-S61, 2001.